Embrace private healthcare to fix the NHS, says former Boots boss
The former boss of Boots has urged the Government to embrace private medical care to fix the NHS, as he backed plans to inject tens of billions of pounds into the struggling health service.
Sebastian James, the former Bullingdon Club member who endorsed Labour last year, said Rachel Reeves is right to propose a £30bn funding boost for the NHS as part of her upcoming spending review.
However, he urged ministers to use the cash to 'grasp the nettle of private provision', as he said that easing pressure on cash-strapped NHS hospitals was key to reducing waiting lists.
Mr James is already working with the NHS to help outsource cataract surgeries as the chief executive of European eye clinic chain Veonet, which runs the SpaMedica business in the UK.
But he said Wes Streeting, the Health Secretary, must go further and faster on working with the private sector after waiting lists recently rose for the first time in seven months.
The backlog now stands at 7.42m, according to data released for the end of March.
'We need radical change that can be achieved by releasing a measurable sum of money,' Mr James, the son of the hereditary peer the 5th Baron Northbourne, told The Telegraph.
'We need a more commercial approach. We have to grasp the nettle of private provision. We understand people's hesitation, but we want to see what's best for the patient.'
The suggestion echoes ideas put forward by Richard Tice, Reform UK's deputy leader.
He has called for the NHS to buy millions more appointments from the independent sector to help address waiting lists, claiming it could help to clear the appointment backlog within two years.
This would go further than the Government's current pledge to offer up to a million extra appointments in private hospitals.
Yet such ideas are controversial as they will stoke fears of creeping privatisation of the NHS and raise concerns about potential profiteering.
Mr James said: 'There are questions about private companies making money. But it's all about how do you square that?
'There are two key things. One, it will still be free at the point of use. And two, the price will be cheaper than what is offered by the public healthcare system.'
Mr James has already held talks with Whitehall officials about his plans for the NHS and he said the Chancellor is right to unleash a significant one-off sum.
'You should borrow to pay for it,' said Mr James, suggesting that £20bn or £30bn would barely move the dial when it comes to the country's £2.8 trillion debt pile.
However, it comes at a time when the Chancellor is already facing a struggle to balance the books.
Ms Reeves will this week deliver her spending review, which is widely expected to unlock an extra £30bn for the NHS over a three-year period.
That will be at the expense of other public services, as she is also plotting real-terms cuts to day-to-day spending across many Whitehall departments.
Such pressures have emerged because of the Chancellor's fiscal rules, which prevent her from borrowing to fund day-day-day spending.
However, Mr James believes that borrowing to fix the waiting list crisis would do far greater good than harm.
He said that SpaMedica's role in providing eye services for the NHS should be a blueprint for ministers to work from, as the company claims to have helped cut waiting times for cataract surgery from 18 months to two weeks since Covid.
It now provides around 70pc of eye care referrals from the NHS, and last year helped to restore the sight of around 200,000 patients.
While it has helped to cut waiting times, SpaMedica is one of many private cataract clinics facing claims of profiteering after they allegedly inflated costs for procedures.
A leaked document from the Health Department, first reported by The Sunday Times, alleged that SpaMedica classed its patients as 'higher complexity', which led to procedures being more expensive than they needed to be.
Campaigners point to the fact that SpaMedica's profits rose from £63.9m to £71.8m in its last financial year, which they say is proof of the company taking the taxpayer for a ride.
SpaMedica has denied any wrongdoing.
However, such allegations reflect the fierce debate surrounding privatisation of the NHS, with many households uncomfortable with the prospect of independent providers making a profit while providing medical services, even if they are free for patients.
Mr James, who ran Boots from 2018 to 2024, is adamant that ministers must ignore such complaints if they are to have any hope of reducing waiting lists.
'We have cut waiting times down from 18 months to two to three weeks,' said Mr James. 'We have eaten away our waiting list.'
This is particularly key for Sir Keir Starmer, who has pledged that 92pc of NHS patients will get an appointment within 18 weeks by the end of the current parliament in 2029.
Ultimately, Mr James argues that private healthcare must be embraced because it is far more efficient than the NHS.
He said that SpaMedica clinics carry out more than 20 cataract surgeries a day, which is almost double that of NHS hospitals.
The fees are also cheaper, he said, as each cataract operation costs SpaMedica £980, compared to around £1,400 on the NHS.
'We've shown that we can do it in our industry, but we need to broaden it out,' he said. 'We could take it area by area, whether that be knee replacements or treating melanomas.
'By working with private healthcare providers, the solution is to save the NHS money.
'We understand people's hesitation, but we want to see what's best for the patient. We're not talking about eradicating the NHS, it's about a partnership.'
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
33 minutes ago
- Medscape
NICE Recommends Earlier Treatments for Chronic Heart Failure
Thousands of patients in England with early-stage chronic heart failure could benefit from earlier access to effective drug therapies under new draft guidance from the National Institute for Health and Care Excellence (NICE). The guidance, which updates NICE's 2018 clinical recommendations, advises earlier treatment for heart failure with reduced ejection fraction ( HFrEF). NICE said that clinical practice is changing and that medicines should be offered up to a year earlier in the treatment pathway. The changes could prevent 3000 deaths and 5500 hospital admissions annually in England, the regulator estimated. Earlier Use of Combination Therapies The four pillars of treatment for HFrEF include: Angiotensin-converting enzyme inhibitors (ACEIs) Beta-blockers (BBs) Mineralocorticoid receptor antagonists (MRAs) Sodium-glucose cotransporter-2 (SGLT2) inhibitors NICE said these drugs should be prescribed earlier, without the need to optimise the dose of any one medicine before introducing another. SGLT2 inhibitors such as empagliflozin and dapagliflozin should now be offered at the start of the treatment pathway, rather than after other medications have been fully titrated – a process that could take over a year. NICE also advised that angiotensin receptor neprilysin inhibitors (ARNIs) should be offered if a person cannot tolerate an ACEI, rather than only to patients stabilised on ACEIs or angiotensin receptor blockers (ARBs). Both SGLT2 inhibitors and ARNIs could now be initiated by GPs with advice from heart failure specialists, potentially speeding up patient access. Responding to Evolving Evidence 'We've been able to review the emerging evidence quickly to keep pace with changes in the treatment landscape and make recommendations that will widen access to effective treatments,' said Eric Power, deputy director in NICE's centre for guidelines. He added that the new approach could help reduce emergency hospital admissions and improve quality of life for people living with heart failure. Updated Diagnostic and Monitoring Advice NICE also updated guidance on diagnosis and monitoring, particularly for iron deficiency and anaemia in patients with HFrEF. Clinicians should: Assess iron status and check for anaemia using transferrin saturation (TSAT), serum ferritin, and haemoglobin Consider intravenous iron for patients with haemoglobin under 150 g/L and TSAT under 20% or ferritin under 100 ng/mL If iron deficiency anaemia is found, alternative causes beyond heart failure should be investigated. Revised Biomarker Recommendations In addition, NICE advised clinicians to be aware that: An NT-proBNP level of less than 400 nanogram per litre (47 pmol per litre) in an untreated person makes a diagnosis of heart failure less likely. The level of serum natriuretic peptide does not differentiate between heart failure with preserved, mildly reduced, and reduced ejection fraction. Obesity, African or African-Caribbean ethnic background, or treatment with a diuretic, an ACEI, an ARNI, an ARB, a beta-blocker, or a MRA could reduce serum natriuretic peptide levels. High levels of natriuretic peptides may also be caused by non-cardiac conditions such as COPD, diabetes, sepsis, and liver or kidney disease. Heart Failure Prevalence Almost one million people in the UK are currently living with heart failure, with 200,000 new diagnoses each year. The average age at diagnosis is 76. Rising life expectancy and obesity are driving the increased incidence and prevalence of the disease.


Associated Press
an hour ago
- Associated Press
Biologic Therapeutic Drugs Technology Analysis and Global Market Forecast Report 2024-2025 & 2029 Featuring Key Players - Merck, F. Hoffmann-La Roche, Johnson & Johnson, Pfizer, & Bristol-Myers Squibb
DUBLIN--(BUSINESS WIRE)--Jun 11, 2025-- The 'Biologic Therapeutic Drugs: Technologies and Global Markets' report has been added to offering. The global market for biologic therapeutic drugs is estimated to increase from $499.2 billion in 2024 to reach $794.5 billion by 2029, at a compound annual growth rate (CAGR) of 9.7% from 2024 through 2029. This report provides an overview of the global biologic therapeutic drug market and analyzes market trends. It includes global revenue ($U.S. millions) for base year data for 2023 and estimated data for 2024. The forecast period is 2024 through 2029. The pharmaceutical industry is undergoing tremendous transformations by focusing more on targeted and personalized therapies. The industry is witnessing a shift from traditional synthetic drugs to biologic therapeutic drugs, which are more efficacious, have better patient outcomes and improve quality of life. Biologic drugs are primarily classified into monoclonal antibodies; vaccines; peptide hormones; cell and gene therapies; and others, which include protein therapeutics (e.g., cytokines, enzymes, blood factors, fusion proteins) and other drugs (e.g., RNA-based therapies). The biopharmaceutical industry has recently been witnessing tremendous growth due to the increasing demand for innovative therapies, such as monoclonal antibodies, cell and gene therapies and vaccines. The demand for these therapies is primarily driven by such factors as the increasing prevalence of chronic diseases, rising healthcare expenditures, increasing awareness, novel product launches and strong pipelines. The biologic approvals by the U.S. Food and Drug Administration (FDA) are increasing year on year, and 2023 was marked by the approval of two breakthrough therapies: the gene editing therapy Casgevy from Vertex Pharmaceutical and Leqembi (lecanemab) from Eisai Inc. The entry of biosimilars into the market is expected to erode the revenues of the current branded products upon patent expiry. The complex manufacturing process, a lack of skilled workforce and high development costs translate to a high cost of therapy, which acts as a major barrier to the market. The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report concludes with an analysis of the competitive landscape, which provides the ranking and share of key players in the global biologic therapeutic drug market. It also has a section dedicated to company profiles that covers such details as overview, key financials, product portfolio and recent developments of key market players. The report includes: Company Profiles Key Attributes: Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Market Overview Chapter 3 Market Dynamics Chapter 4 Regulatory Landscape Chapter 5 Emerging Technologies and Developments Chapter 6 Market Segmentation Analysis Chapter 7 Competitive Intelligence Chapter 8 Sustainability in Biologics Therapeutic Drug Market: An ESG Perspective Chapter 9 Appendix For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH TECHNOLOGY PHARMACEUTICAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 06/11/2025 08:33 AM/DISC: 06/11/2025 08:32 AM


Associated Press
an hour ago
- Associated Press
Oncology Diagnostics Global Markets Report 2025: Expanding Cancer Screening and Enhanced Access to Advanced Technologies Bolster Opportunities - Forecast to 2029
DUBLIN--(BUSINESS WIRE)--Jun 11, 2025-- The 'Oncology Diagnostics: Global Markets' report has been added to offering. The global market for oncology diagnostics is estimated to increase from $77.6 billion in 2024 to reach $101.5 billion by 2029, at a compound annual growth rate (CAGR) of 5.5% from 2024 through 2029. The base year for the study is 2023, 2024 is the estimated year, with projections through 2029, including compound annual growth rates (CAGRs) for the forecast period. This report analyzes the oncology diagnostics market and the competitive landscape. The profiles of several leading companies, including their revenues, product portfolios and recent activities are also examined. The report analyzes market dynamics, including drivers, limitations, challenges and opportunities, and discusses current and potential market size. The report will enable companies in the industry to make informed decisions about the production and licensing of goods and services. The oncology diagnostics market is growing at a steady rate driven by the increasing incidence and the prevalence of a wide range of cancers globally, R&D and new product launches by the major players in the market, strategic initiatives by the major players, and increasing numbers of private diagnostic centers in emerging markets. Key Attributes: The report includes: Key Topics Covered: Chapter 1 Executive Summary Chapter 2 Market Overview Chapter 3 Market Dynamics Chapter 4 Regulatory Landscape Chapter 5 Emerging Technologies and Developments Chapter 6 Oncology Diagnostics Market Chapter 7 Competitive Intelligence Chapter 8 Sustainability in the Market for Oncology Diagnostics: An ESG Perspective Chapter 9 Appendix List of Tables Summary Table: Global Market for Oncology Diagnostics, by Product Type, Through 2029 Table 1: Global Incidence of All Cancer Cases, by WHO Region, 2022-2045 Table 2: Global Incidence of Cancer Cases, Both Sexes, by Cancer Type, 2022 Table 3: Cancer Treatments Based on Specific Tests Table 4: Select FDA-Approved AI-Associated/Associable-Equipped Medical Devices Table 5: Selected Patent Grants in Oncology Diagnostics, 2023-2025 Table 6: Global Oncology Diagnostics Market, by Product Type, Through 2029 Table 7: Global Diagnostics Imaging Market, by Region, Through 2029 Table 8: Global Endoscopy Market, by Region, Through 2029 Table 9: Global Tumor Biomarker Tests Market, by Region, Through 2029 Table 10: Global Biopsy Devices Market, by Region, Through 2029 Table 11: Global H&E and Special Stains Diagnostics Market, by Region, Through 2029 Table 12: Global IHC Oncology Diagnostics Market, by Region, Through 2029 Table 13: Global ISH Oncology Diagnostics Market, by Region, Through 2029 Table 14: Global PCR Oncology Diagnostics Market, by Region, Through 2029 Table 15: Global NGS Oncology Diagnostics Market, by Region, Through 2029 Table 16: Global Other Oncology Diagnostics Tests Market, by Region, Through 2029 Table 17: Global Oncology Diagnostics Market, by Application, Through 2029 Table 18: Global Breast Cancer Diagnostics Market, by Region, Through 2029 Table 19: Global Lung Cancer Diagnostics Market, by Region, Through 2029 Table 20: Global Colorectal Cancer Diagnostics Market, by Region, Through 2029 Table 21: Global Prostate Cancer Diagnostics Market, by Region, Through 2029 Table 22: Global Gastric Cancer Diagnostics Market, by Region, Through 2029 Table 23: Global Oncology Diagnostics Market in Other Cancer Applications, by Region, Through 2029 Table 24: Global Oncology Diagnostics Market, by End User, Through 2029 Table 25: Global Oncology Diagnostics Market in Hospitals, Cancer Centers and Clinics, Through 2029 Table 26: Global Oncology Diagnostics Market in Diagnostic Imaging and Reference Laboratories, Through 2029 Table 27: Global Oncology Diagnostics Market in Other End Uses, Through 2029 Table 28: Global Oncology Diagnostics Market, by Region, Through 2029 Table 29: North American Oncology Diagnostics Market, by Country, Through 2029 Table 30: U.S. Oncology Diagnostics Market, by Product Type, Through 2029 Table 31: U.S. Oncology Diagnostics Market, by Application, Through 2029 Table 32: U.S. Oncology Diagnostics Market, by End User, Through 2029 Table 33: Canadian Oncology Diagnostics Market, by Product Type, Through 2029 Table 34: Canadian Oncology Diagnostics Market, by Application, Through 2029 Table 35: Canadian Oncology Diagnostics Market, by End User, Through 2029 Table 36: Mexican Oncology Diagnostics Market, by Product Type, Through 2029 Table 37: Mexican Oncology Diagnostics Market, by Application, Through 2029 Table 38: Mexican Oncology Diagnostics Market, by End User, Through 2029 Table 39: European Oncology Diagnostics Market, by Country, Through 2029 Table 40: Cancer Incidence and Mortality Numbers in Germany, Both Sexes, 2022 Table 41: German Oncology Diagnostics Market, by Product Type, Through 2029 Table 42: German Oncology Diagnostics Market, by Application, Through 2029 Table 43: German Oncology Diagnostics Market, by End User, Through 2029 Table 44: Cancer Incidence and Mortality Numbers in France, Both Sexes, 2022 Table 45: French Oncology Diagnostics Market, by Product Type, Through 2029 Table 46: French Oncology Diagnostics Market, by Application, Through 2029 Table 47: French Oncology Diagnostics Market, by End User, Through 2029 Table 48: New Cases of Cancer Diagnosed Each Year in the U.K., 2021 Table 49: The U.K. Oncology Diagnostics Market, by Product Type, Through 2029 Table 50: The U.K. Oncology Diagnostics Market, by Application, Through 2029 Table 51: The U.K. Oncology Diagnostics Market, by End User, Through 2029 Table 52: Cancer Incidence and Mortality Numbers in Italy, Both Sexes, 2022 Table 53: Italian Oncology Diagnostics Market, by Product Type, Through 2029 Table 54: Italian Oncology Diagnostics Market, by Application, Through 2029 Table 55: Italian Oncology Diagnostics Market, by End User, Through 2029 Table 56: Cancer Incidence and Mortality Numbers in Spain, Both Sexes, 2022 Table 57: Spanish Oncology Diagnostics Market, by Product Type, Through 2029 Table 58: Spanish Oncology Diagnostics Market, by Application, Through 2029 Table 59: Spanish Oncology Diagnostics Market, by End User, Through 2029 Table 60: Rest of European Countries' Oncology Diagnostics Market, by Product Type, Through 2029 Table 61: Rest of European Countries' Oncology Diagnostics Market, by Application, Through 2029 Table 62: Rest of European Countries' Oncology Diagnostics Market, by End User, Through 2029 Table 63: Asia-Pacific Oncology Diagnostics Market, by Country, Through 2029 Table 64: Cancer Incidence and Mortality Numbers in China, Both Sexes, 2022 Table 65: Chinese Oncology Diagnostics Market, by Product Type, Through 2029 Table 66: Chinese Oncology Diagnostics Market, by Application, Through 2029 Table 67: Chinese Oncology Diagnostics Market, by End User, Through 2029 Table 68: Cancer Incidence and Mortality Numbers in Japan, Both Sexes, 2022 Table 69: Japanese Oncology Diagnostics Market, by Product Type, Through 2029 Table 70: Japanese Oncology Diagnostics Market, by Application, Through 2029 Table 71: Japanese Oncology Diagnostics Market, by End User, Through 2029 Table 72: Cancer Incidence and Mortality Numbers in India, Both Sexes, 2022 Table 73: Indian Oncology Diagnostics Market, by Product Type, Through 2029 Table 74: Indian Oncology Diagnostics Market, by Application, Through 2029 Table 75: Indian Oncology Diagnostics Market, by End User, Through 2029 Table 76: Rest of Asia-Pacific Oncology Diagnostics Market, by Product Type, Through 2029 Table 77: Rest of Asia-Pacific Oncology Diagnostics Market, by Application, Through 2029 Table 78: Rest of Asia-Pacific Oncology Diagnostics Market, by End User, Through 2029 Table 79: South American Oncology Diagnostics Market, by Country, Through 2029 Table 80: Brazilian Oncology Diagnostics Market, by Product Type, Through 2029 Table 81: Brazilian Oncology Diagnostics Market, by Application, Through 2029 Table 82: Brazilian Oncology Diagnostics Market, by End User, Through 2029 Table 83: Argentine Oncology Diagnostics Market, by Product Type, Through 2029 Table 84: Argentine Oncology Diagnostics Market, by Application, Through 2029 Table 85: Argentine Oncology Diagnostics Market, by End User, Through 2029 Table 86: Rest of South American Oncology Diagnostics Market, by Product Type, Through 2029 Table 87: Rest of South American Oncology Diagnostics Market, by Application, Through 2029 Table 88: Rest of South American Oncology Diagnostics Market, by End User, Through 2029 Table 89: Middle East and African Oncology Diagnostics Market, by Product Type, Through 2029 Table 90: Middle East and African Oncology Diagnostics Market, by Application, Through 2029 Table 91: Middle East and African Oncology Diagnostics Market, by End User, Through 2029 Table 92: Company Shares in the Oncology Diagnostics Market, 2023 Table 93: ESG: Environmental Overview Table 94: ESG: Social Overview Table 95: ESG: Governance Overview Table 96: Abbreviations Used in this Report Table 97: Abbott: Company Snapshot Table 98: Abbott: Financial Performance, FY 2022 and 2023 Table 99: Abbott: Product Portfolio Table 100: Agilent Technologies Inc.: Company Snapshot Table 101: Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024 Table 102: Agilent Technologies Inc.: Product Portfolio Table 103: Agilent Technologies Inc.: News/Key Developments, 2024 Table 104: BD: Company Snapshot Table 105: BD: Financial Performance, FY 2023 and 2024 Table 106: BD: Product Portfolio Table 107: bioMerieux: Company Snapshot Table 108: bioMerieux: Financial Performance, FY 2022 and 2023 Table 109: bioMerieux: Product Portfolio Table 110: Bio-Rad Laboratories Inc.: Company Snapshot Table 111: Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024 Table 112: Bio-Rad Laboratories Inc.: Product Portfolio Table 113: Danaher Corp.: Company Snapshot Table 114: Danaher Corp.: Financial Performance, FY 2022 and 2023 Table 115: Danaher Corp.: Product Portfolio Table 116: Danaher Corp.: News/Key Developments, 2023 Table 117: F. Hoffmann-La Roche Ltd.: Company Snapshot Table 118: F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024 Table 119: F. Hoffmann-La Roche Ltd.: Product Portfolio Table 120: F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024 and 2025 Table 121: GE HealthCare: Company Snapshot Table 122: GE HealthCare: Financial Performance, FY 2023 and 2024 Table 123: GE HealthCare: Product Portfolio Table 124: GE HealthCare: News/Key Developments, 2024 Table 125: Illumina Inc.: Company Snapshot Table 126: Illumina Inc.: Financial Performance, FY 2023 and 2024 Table 127: Illumina Inc.: Product Portfolio Table 128: Illumina Inc.: News/Key Developments, 2024 Table 129: Koninklijke Philips N.V.: Company Snapshot Table 130: Koninklijke Philips N.V.: Financial Performance, FY 2023 and 2024 Table 131: Koninklijke Philips N.V.: Product Portfolio Table 132: Merck KGaA: Company Snapshot Table 133: Merck KGaA: Financial Performance, FY 2022 and 2023 Table 134: Merck KGaA: Product Portfolio Table 135: Myriad Genetics Inc.: Company Snapshot Table 136: Myriad Genetics Inc.: Financial Performance, FY 2022 and 2023 Table 137: Myriad Genetics Inc.: Product Portfolio Table 138: Myriad Genetics Inc.: News/Key Developments, 2025 Table 139: Qiagen: Company Snapshot Table 140: Qiagen: Financial Performance, FY 2022 and 2023 Table 141: Qiagen: Product Portfolio Table 142: Siemens Healthineers AG: Company Snapshot Table 143: Siemens Healthineers AG: Financial Performance, FY 2023 and 2024 Table 144: Siemens Healthineers AG: Product Portfolio Table 145: Siemens Healthineers AG: News/Key Developments, 2024 Table 146: Thermo Fisher Scientific Inc.: Company Snapshot Table 147: Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023 Table 148: Thermo Fisher Scientific Inc.: Product Portfolio Table 149: Thermo Fisher Scientific Inc.: News/Key Developments, 2023 Table 150: ZytoVision GmbH: Company Snapshot Table 151: ZytoVision GmbH: Product Portfolio Table 152: Emerging Startups in Oncology Diagnostics Market List of Figures Summary Figure: Global Market Shares of Oncology Diagnostics, by Product Type, 2023 Figure 1: Porter's Five Forces Analysis of the Oncology Market Figure 2: Market Dynamics of Oncology Diagnostics Figure 3: Global Incidence Shares of All Cancer Cases, by Region, 2022 Figure 4: Number of FDA-Approved Companion Diagnostic Devices, 1997-2024 Figure 5: Emerging Trends and Technologies in Oncology Diagnostics Figure 6: Share of Global Market for Oncology Diagnostics, by Product Type, 2023 Figure 7: Share of Global Market for Oncology Diagnostics, by Application, 2023 Figure 8: Shares of Global Market for Oncology Diagnostics, by End User, 2023 Figure 9: Share of Global Market for Oncology Diagnostics, by Region, 2023 Figure 10: Share of North American Market for Oncology Diagnostics, by Country, 2023 Figure 11: Share of European Market for Oncology Diagnostics, by Country, 2023 Figure 12: Breast Cancer Screening Rates in Europe, by Country, 2012 vs. 2022 Figure 13: Cervical Cancer Screening Rates in European Countries, 2022 Figure 14: Colorectal Cancer Screening Rates in European Countries, 2022 Figure 15: Current and Forecasted Cancer Prevalence in the U.K., 2020-2040 Figure 16: Shares of Cancer Cases in Asia and Oceania, Both Sexes, by Cancer Type, 2022 Figure 17: Shares of All Cancer Mortality Cases in Asia and Oceania, Both Sexes, by Cancer Type, 2022 Figure 18: Share of Asia-Pacific Market for Oncology Diagnostics, by Country, 2023 Figure 19: Share of South American Market for Oncology Diagnostics, by Country, 2023 Figure 20: Share of the Global Market for Oncology Diagnostics, by Company, 2023 Figure 21: ESG Pillars Figure 22: Advantages of ESG for Companies Figure 23: Abbott: Revenue Share, by Business Unit, FY 2023 Figure 24: Abbott: Revenue Share, by Country/Region, FY 2023 Figure 25: Agilent Technologies Inc.: Revenue Share, by Business Unit, FY 2024 Figure 26: Agilent Technologies Inc.: Revenue Share, by Country/Region, FY 2024 Figure 27: BD: Revenue Share, by Business Unit, FY 2024 Figure 28: BD: Revenue Share, by Country/Region, FY 2024 Figure 29: bioMerieux: Revenue Share, by Business Unit, FY 2023 Figure 30: bioMerieux: Revenue Share, by Region, FY 2023 Figure 31: Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024 Figure 32: Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024 Figure 33: Danaher Corp.: Revenue Share, by Business Unit, FY 2023 Figure 34: Danaher Corp.: Revenue Share, by Country/Region, FY 2023 Figure 35: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024 Figure 36: F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024 Figure 37: GE HealthCare: Revenue Share, by Business Unit, FY 2024 Figure 38: GE HealthCare: Revenue Share, by Country/Region, FY 2024 Figure 39: Illumina Inc.: Revenue Share, by Business Unit, FY 2024 Figure 40: Illumina Inc.: Revenue Share, by Country/Region, FY 2024 Figure 41: Koninklijke Philips N.V.: Revenue Share, by Business Unit, FY 2024 Figure 42: Koninklijke Philips N.V.: Revenue Share, by Country/Region, FY 2023 Figure 43: Merck KGaA: Market Share, by Business Unit, 2023 Figure 44: Merck KGaA: Revenue Share, by Country/Region, 2023 Figure 45: Myriad Genetics Inc.: Revenue Share, by Business Unit, 2023 Figure 46: Myriad Genetics Inc.: Revenue Share, by Country/Region, 2023 Figure 47: Qiagen: Revenue Share, by Business Unit, FY 2023 Figure 48: Qiagen: Revenue Share, by Country/Region, FY 2023 Figure 49: Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2024 Figure 50: Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2024 Figure 51: Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2023 Figure 52: Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2023 Companies Featured For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH TECHNOLOGY HEALTH ONCOLOGY SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 06/11/2025 08:39 AM/DISC: 06/11/2025 08:37 AM